Kamada Ltd. (KMDA)
NASDAQ: KMDA · IEX Real-Time Price · USD
5.84
+0.06 (1.00%)
Jul 22, 2024, 10:33 AM EDT - Market open
Kamada Employees
Kamada had 378 employees as of December 31, 2023. The number of employees decreased by 2 or -0.53% compared to the previous year.
Employees
378
Change (1Y)
-2
Growth (1Y)
-0.53%
Revenue / Employee
$395,622
Profits / Employee
$32,958
Market Cap
335.54M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ModivCare | 21,200 |
| Nevro | 1,215 |
| ADC Therapeutics | 274 |
| Nautilus Biotechnology | 167 |
| AC Immune | 161 |
| Foghorn Therapeutics | 116 |
| Cabaletta Bio | 103 |
| Inozyme Pharma | 59 |
KMDA News
- 2 months ago - Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance - GlobeNewsWire
- 2 months ago - Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - GlobeNewsWire
- 4 months ago - Kamada Issues 2024 CEO Letter to Shareholders - GlobeNewsWire
- 4 months ago - Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability - GlobeNewsWire
- 5 months ago - Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 - GlobeNewsWire
- 8 months ago - KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® - PRNewsWire
- 8 months ago - Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years - GlobeNewsWire
- 9 months ago - Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance - GlobeNewsWire